Results 21 to 30 of about 16,645 (269)

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. [PDF]

PLoS ONE, 2018
Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation effects of direct and indirect FXa inhibitors.To evaluate
Genmin Lu, Polly Pine, Janet M Leeds, Francis DeGuzman, Pratikhya Pratikhya, Joyce Lin, John Malinowski, Stanley J Hollenbach, John T Curnutte, Pamela B Conley   +9 more
doaj   +1 more source

Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY

Thrombosis Update, 2021
Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism treatment or stroke prevention in atrial fibrillation.
Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, Christina Köhler, Luise Tittl, Martin Bornhäuser   +5 more
doaj   +1 more source

Edoxaban [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada, Danial E, Baker, Kyle, Ingram   +2 more
openaire   +2 more sources

Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats

TH Open, 2021
Coagulation–fibrinolytic system activity shows daily rhythmicity, with hypercoagulability in the morning and hypocoagulability in the evening. Consequently, the efficacy of anticoagulants may be influenced by their dosing time.
Naoto Nagata, Muneo Kawasumi, Akio Fujimura, Hitoshi Ando   +3 more
doaj   +1 more source

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

Thrombosis Journal, 2020
Background Dual therapy with a direct oral anticoagulant (DOAC) plus a P2Y12 receptor inhibitor is recommended in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention.
Ippei Ikushima, Takaaki Akasaka, Yoshiyuki Morishima, Atsushi Takita, Tomoko Motohashi, Tetsuya Kimura   +5 more
doaj   +1 more source

Edoxaban in patients with atrial fibrillation [PDF]

Therapeutic Advances in Cardiovascular Disease, 2016
Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF). The aim of this review is to focus specifically on the efficacy and safety profile of edoxaban in patients with AF from preclinical development through the phase III trial ...
Alon Eisen, Christian T. Ruff
openaire   +3 more sources

Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban

Neurological Research and Practice, 2021
Background Direct oral anticoagulants (DOAC) including edoxaban are increasingly used for stroke prevention in atrial fibrillation. Despite treatment, annual stroke rate in these patients remains 1–2%.
Florian Härtig, Ingvild Birschmann, Andreas Peter, Sebastian Hörber, Matthias Ebner, Matthias Sonnleitner, Charlotte Spencer, Paula Bombach, Maria-Ioanna Stefanou, Johannes Tünnerhoff, Annerose Mengel, Joachim Kuhn, Ulf Ziemann, Sven Poli   +13 more
doaj   +1 more source

Study of weight variation and dissolution of Edoxaban split tablets in pharmacy practice [PDF]

Pharmaceutical Sciences Asia, 2022
Edoxaban is available in 60 mg, 30 mg, and 15 mg unscored film-coated tablets. Tablet splitting may be an option to reduce medication costs and reduce the country’s budget.
Mantiwee Nimworapan, Sinwisuth Sutheechai, Wanwarang Wongcharoen, Arintaya Phrommintikul, Suntara Eakanunkul   +4 more
doaj   +1 more source

Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]

, 2020
OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD, Akgün, T, Camm, AJ, Emren, V, Kanat, S, Karacağlar, E, Kepez, A, Kul, Ş, Tülüce, K, Türk, UÖ, Yakar Tülüce, S, Özel, E, Şimşek, E   +12 more
core   +1 more source

Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation

Cardiology and Therapy, 2023
Introduction Treatment adherence and persistence impact the effectiveness of edoxaban for the prevention of thromboembolism in patients with atrial fibrillation (AF).
Giuseppe Patti, Rosa Wang, Xiaocong Li Marston, Yu-Chen Yeh, Lisa Zimmermann, Xin Ye, Xin Gao, Bernd Brüggenjürgen   +7 more
doaj   +1 more source